Interpace Biosciences (STU:PF42) Stock Based Compensation: €0.02 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PF42 Interpace Biosciences Inc STU:PF42
41 GF Score
Price €1.34
GF Value €0.17
! 5 Warning Signs
View Full Analysis

What is Interpace Biosciences Stock Based Compensation?

Interpace Biosciences STU:PF42 +0.75% 41 Stock Based Compensation is €0.02 Mil as of Jun. 2026. GuruFocus rates STU:PF42 with a GF Score™ of 41/100 and a GF Value™ of €0.17. The stock has 5 warning signs investors should review.

Interpace Biosciences's Stock Based Compensation for the three months ended in Jun. 2026 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €0.02 Mil.

Interpace Biosciences Stock Based Compensation Related Terms

Interpace Biosciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Interpace Biosciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interpace Biosciences Stock Based Compensation Chart

Interpace Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.21 1.23 0.58 0.28 0.03

Interpace Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.00 0.00 0.00
STU:PF42
41GF Score
Interpace Biosciences Inc STU:PF42
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Interpace Biosciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02 Mil.

What does a Stock Based Compensation of €0.02 Mil mean?
Interpace Biosciences (STU:PF42) has a Stock Based Compensation of €0.02 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Interpace Biosciences and its competitors.
Is Interpace Biosciences' Stock Based Compensation too high?
Interpace Biosciences' current Stock Based Compensation is €0.02 Mil. Overall, Interpace Biosciences has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Stock Based Compensation compare to PRPO and ADVB?
Interpace Biosciences' Stock Based Compensation of €0.02 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Interpace Biosciences and its competitors. Interpace Biosciences's current Stock Based Compensation is €0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Interpace Biosciences (STU:PF42) has a current Stock Based Compensation of €0.02 Mil. The stock's GF Value™ is €0.17, compared to a current price of €1.34 — trading 688.2% above its estimated fair value. The current Stock Based Compensation is €0.02 Mil. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Interpace Biosciences (STU:PF42), the current Stock Based Compensation is €0.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Interpace Biosciences (STU:PF42) Overvalued in 2026?

Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued. The current stock price of €1.34 is trading 688.2% above its estimated GF Value™ of €0.17.

Key valuation signals for STU:PF42:

  • Stock Based Compensation: €0.02 Mil
  • GF Value™: €0.17 vs. price of €1.34 (688.2% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the STU:PF42 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Interpace Biosciences Business Description

Other Exchanges IDXG:USA
Address 2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score

Get the complete analysis for STU:PF42

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.34
Price
€0.17
GF Value